p.102 抽出テキスト

Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 September 25, 2018 e373 CLINICAL STATEMENTS AND GUIDELINES

S7.7.2-8.	 Gatzoulis KA, Tsiachris D, Arsenos P, et al. Prognostic value of pro-

grammed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J Cardiol. 2014;176:1449–51.

7.7.3 Left Ventricular Assist Device

S7.7.3-1.	 Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverterdefibrillator use in patients with left ventricular assist devices: a systematic review and meta-analysis. JACC Heart Fail. 2016;4:772–9. S7.7.3-2.	 Cantillon DJ, Tarakji KG, Kumbhani DJ, et al. Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm. 2010;7:466–71. S7.7.3-3.	 Raasch H, Jensen BC, Chang PP, et al. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. Am Heart J. 2012;164:373–8. S7.7.3-4.	 Garan AR, Yuzefpolskaya M, Colombo PC, et al. Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? J Am Coll Cardiol. 2013;61:2542–50. S7.7.3-5.	 Refaat MM, Tanaka T, Kormos RL, et al. Survival benefit of implantable cardioverter-defibrillators in left ventricular assist device-supported heart failure patients. J Card Fail. 2012;18:140–5. S7.7.3-6.	 Enriquez AD, Calenda B, Miller MA, et al. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2013;6:668–74. S7.7.3-7.	 Lee W, Tay A, Subbiah RN, et al. Impact of implantable cardioverter defibrillators on survival of patients with centrifugal left ventricular assist devices. Pacing Clin Electrophysiol. 2015;38:925–33. S7.7.3-8.	 Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751–7. S7.7.3-9.	 Slaughter MS, Meyer AL, Birks EJ. Destination therapy with left ven-

tricular assist devices: patient selection and outcomes. Curr Opin Cardiol. 2011;26:232–6.

7.7.4 ICD Use After Heart Transplantation

S7.7.4-1.	 Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail. 2009;2:197–201. S7.7.4-2.	 McDowell DL, Hauptman PJ. Implantable defibrillators and cardiac resynchronization therapy in heart transplant recipients: results of a national survey. J Heart Lung Transplant. 2009;28:847–50. S7.7.4-3.	 Neylon A, Canniffe C, Parlon B, et al. Implantable cardioverter-defibrillators in a heart transplant population: A single-center experience. J Heart Lung Transplant. 2016;35:682–4. S7.7.4-4.	 Vakil K, Taimeh Z, Sharma A, et al. Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. Heart Rhythm. 2014;11:1684–90. S7.7.4-5.	 Vaseghi M, Lellouche N, Ritter H, et al. Mode and mechanisms

of death after orthotopic heart transplantation. Heart Rhythm. 2009;6:503–9.

7.8 Neuromuscular Disorders

S7.8-1.	 Bhakta D, Groh MR, Shen C, et al. Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. Am Heart J. 2010;160:1137–41, 41. S7.8-2.	 Merino JL, Carmona JR, Fernandez-Lozano I, et al. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation. Circulation. 1998;98:541–6. S7.8-3.	 Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverterdefibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492–8. S7.8-4.	 van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493–500. S7.8-5.	 Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sud-

den death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209–10. S7.8-6.	 Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk

stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250–60. S7.8-7.	 Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79–83. S7.8-8.	 Russo V, Nigro G. ICD role in preventing sudden cardiac death in Emery-Dreifuss muscular dystrophy with preserved myocardial function: 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Europace. 2015;17:337. S7.8-9.	 Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688–97. S7.8-10.	 Lallemand B, Clementy N, Bernard-Brunet A, et al. The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implications. Heart. 2012;98:291–6. S7.8-11.	 Nazarian S, Wagner KR, Caffo BS, et al. Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy. Pacing Clin Electrophysiol. 2011;34:171–6. S7.8-12.	 Tanawuttiwat T, Wagner KR, Tomaselli G, et al. Left ventricular dysfunction and conduction disturbances in patients with myotonic muscular dystrophy type I and II. JAMA Cardiology. 2017;2:225–8. S7.8-13.	 Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population. J Cardiovasc Electrophysiol. 2011;22:1369–75. S7.8-14.	 Laurent V, Pellieux S, Corcia P, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol. 2011;150:54–8. S7.8-15.	 Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. 2012;9:1890–5. S7.8-16.	 Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408. S7.8-17.	 Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. Circulation. 2008;117:e350–408. S7.8-18.	 Brembilla-Perrot B, Luporsi JD, Louis S, et al. Long-term follow-up of patients with myotonic dystrophy: an electrocardiogram every year is not necessary. Europace. 2011;13:251–7. S7.8-19.	 Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio-

ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II Pacing. Clin Electrophysiol. 2012;35:1262–9.

7.9 Cardiac Channelopathies

S7.9-1.	 Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6–15. S7.9-2.	 Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51–9. S7.9-3.	 Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inherited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183–9. S7.9-4.	 Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59:37–45. S7.9-5.	 Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69–74. S7.9-6.	 Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3

long-QT syndrome: an international multicenter study. Circulation. 2016;134:872–82.

Downloaded from http://ahajournals.org by on October 7, 2026